Epileptic seizures associated with progressive multifocal leukoencephalopathy in HIV-infected patients in Korea

Hyun Kyung Kim1, Ji Yun Kang1, Seo-Young Lee2

  • 1Department of Neurology, National Medical Center, Seoul, Korea.

PubMed

Insights

HIV-infected patients with progressive multifocal leukoencephalopathy (PML) have a high risk of seizures. Cognitive impairment and extensive brain lesions on MRI increase this risk, even at later disease stages.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Oncology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, demyelinating disease affecting the central nervous system.
  • PML is often associated with opportunistic infections in immunocompromised individuals, particularly those with Human Immunodeficiency Virus (HIV).
  • Seizures are a potential neurological complication of PML, but their incidence and risk factors in specific populations require further investigation.

Purpose of the Study:

  • To determine the incidence of seizures in Korean patients with HIV-associated PML.
  • To identify clinical and radiological risk factors associated with seizure development in this patient cohort.
  • To understand the temporal relationship between PML diagnosis and seizure onset.

Main Methods:

  • Retrospective analysis of 34 Korean patients diagnosed with HIV-associated PML.
  • Data collection included patient demographics, clinical history, neurological examinations, and brain Magnetic Resonance Imaging (MRI) findings.
  • Statistical analysis was performed to identify factors correlating with seizure occurrence.

Main Results:

  • 14 out of 34 patients (41.2%) developed epileptic seizures during a median follow-up of 82 months.
  • The median time from PML diagnosis to seizure onset was 44 months (range: 0-133 months).
  • Seizure development was significantly associated with cognitive impairment and the presence of multiple or diffuse brain lesions on MRI.

Conclusions:

  • HIV-infected patients with PML exhibit a substantial risk of developing seizures.
  • Cognitive impairment and extensive/diffuse brain lesions on MRI are key indicators of increased seizure risk.
  • This underscores the importance of monitoring for seizures throughout the course of PML in HIV-infected individuals, irrespective of disease stage.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
230
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
445
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
435
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
219
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
473
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
696